Worth reading
59In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
3100
Millions of yenWording
Avoiding a definitive answer
How definitive the wording is.Revised forecast
Fiscal year ending March 2026 · Full yearPrevious forecast published 7 August 2025Net Sales166,000→168,000Millions of yen
+1.2%
Operating profit30,000→33,000Millions of yen
+10.0%
Profit attributable to owners of the parent24,000→26,300Millions of yen
+9.6%
Net income per share356.2→390.2yen and sen
+9.5%
The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Reason for the revision
前立腺癌治療剤「アーリーダ」の共同販促契約改定に伴い同製品の売上収益を当社で計上することとなったこと、販売費及び一般管理費と研究開発費が減少する見込みとなったこと。
Previous-period results売上収益：160,232百万円（2025年3月期）。親会社の所有者に帰属する当期利益の前期実績額はNot disclosed（対前期増減率は△19.2％）。
Dividend forecast revisionNo revision
Consolidated / non-consolidatedConsolidated
| Item | Details |
|---|---|
| Net Sales | 166,000 Millions of yen → 168,000 Millions of yen（+1.2%） |
| Operating profit | 30,000 Millions of yen → 33,000 Millions of yen（+10.0%） |
| Profit attributable to owners of the parent | 24,000 Millions of yen → 26,300 Millions of yen（+9.6%） |
| Net income per share | 356.2 yen and sen → 390.2 yen and sen |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 7 August 2025 |
| Previous-period results | 売上収益：160,232百万円（2025年3月期）。親会社の所有者に帰属する当期利益の前期実績額はNot disclosed（対前期増減率は△19.2％）。 |
| Reason for the revision | 前立腺癌治療剤「アーリーダ」の共同販促契約改定に伴い同製品の売上収益を当社で計上することとなったこと、販売費及び一般管理費と研究開発費が減少する見込みとなったこと。 |
| Dividend forecast revision | No revision |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
Ordinary incomeDetails and amount of extraordinary loss
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.前立腺癌治療剤「アーリーダ」の共同販促契約改定により、同製品の売上収益を当社で計上することになったため。また、販売費及び一般管理費と研究開発費が減少する見込みとなったため。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.